We are live on ! Find out more
PVCT

Provectus Biopharmaceuticals
PVCT

Delisted

PVCT was delisted on the 13th of October, 2016.

6 hedge funds and large institutions have $14K invested in Provectus Biopharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding

Funds holding: 3 → 6 (+3)

Holders
6
Holders Change
+3
Holders Change %
+100%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Sellers

No sellers this quarter

PVCT Hedge Fund Activity: Q3 2018 in Review

6 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Provectus Biopharmaceuticals (PVCT) for Q3 2018, worth a combined $14K — up 27% from $11K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new PVCT positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Cutter & Co Brokerage, opening a new position worth an estimated $2K.

  • 6 institutional investors held Provectus Biopharmaceuticals (PVCT) as of Q3 2018, up from 3 in Q2 2018.
  • Funds reported $14K of Provectus Biopharmaceuticals stock for Q3 2018, up 27% quarter-over-quarter.
  • 3 funds opened new Provectus Biopharmaceuticals positions in Q3 2018 and 0 closed out, a net change of +3 holders.
  • The largest Provectus Biopharmaceuticals buyer in Q3 2018 was Cutter & Co Brokerage, an estimated $2K added.

Based on aggregated 13F filings for Q3 2018.